These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 15213291)

  • 1. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
    Lincoln TM
    Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
    [No Abstract]   [Full Text] [Related]  

  • 2. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
    Burnett AL
    Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 4. Rationale for androgens and erectile dysfunction in 2006.
    Roumeguère T
    Eur Urol; 2006 Nov; 50(5):898-900. PubMed ID: 16893603
    [No Abstract]   [Full Text] [Related]  

  • 5. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 6. [Viagra landing: the dawn of sexual science in cardiology].
    Ishikura F
    J Cardiol; 1999 Sep; 34(3):163-7. PubMed ID: 10500978
    [No Abstract]   [Full Text] [Related]  

  • 7. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Rosen RC; Shaw JW
    Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

  • 10. [Patients ask for sildenafil--how to treat?].
    Lukkarinen O; Tapanainen J
    Duodecim; 1999; 115(7):807-10. PubMed ID: 11859515
    [No Abstract]   [Full Text] [Related]  

  • 11. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of non-arteritic ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
    Tsertsvadze A
    Am J Ophthalmol; 2009 Oct; 148(4):625; author reply 625-6. PubMed ID: 19782802
    [No Abstract]   [Full Text] [Related]  

  • 13. Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
    Lee AG; Newman NJ
    Am J Ophthalmol; 2005 Oct; 140(4):707-8. PubMed ID: 16226524
    [No Abstract]   [Full Text] [Related]  

  • 14. Unexpected insights into pelvic function following phosphodiesterase manipulation--what's next for urology?
    McVary KT
    Eur Urol; 2006 Dec; 50(6):1153-6. PubMed ID: 17045387
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 16. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
    Pickard R
    Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
    [No Abstract]   [Full Text] [Related]  

  • 17. [How I treat and manage erectile dysfunction in diabetics].
    Buvat J
    Journ Annu Diabetol Hotel Dieu; 2006; ():185-203. PubMed ID: 17051861
    [No Abstract]   [Full Text] [Related]  

  • 18. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual loss with erectile dysfunction medications.
    Wooltorton E
    CMAJ; 2006 Aug; 175(4):355. PubMed ID: 16870715
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphodiesterase inhibitors.
    Boswell-Smith V; Spina D; Page CP
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.